27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Novartis AG (NYSE:NVS) has halted a Phase 2 trial of CFZ533 (iscalimab) in kidney transplant patients.
- The decision follows interim data that showed iscalimab was not as good as tacrolimus-based treatment in preventing organ rejection.
- Iscalimab's study in liver transplant continues, and additional studies exploring the drug as a potential treatment in other conditions.
- Novartis is continuing to review the data from the CIRRUS-1 study. Once complete, the company will share the results with the broader scientific community.
- Price Action: NVS shares closed 0.54% lower at $92.15 on Thursday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!